An Open-Label, Single-Arm, Multicenter Pilot Study to Evaluate Safety, Tolerability, and Efficacy of ALN-PCSSC in Subjects With Homozygous Familial Hypercholesterolemia
Phase of Trial: Phase II
Latest Information Update: 22 Jul 2017
At a glance
- Drugs Inclisiran (Primary)
- Indications Hyperlipoproteinaemia type IIa
- Focus Therapeutic Use
- Acronyms ORION-2
- Sponsors The Medicines Company
- 16 May 2017 Planned End Date changed from 1 May 2018 to 31 Dec 2018.
- 16 May 2017 Planned primary completion date changed from 1 Nov 2017 to 1 Nov 2018.
- 08 Jan 2017 Status changed from not yet recruiting to recruiting, as reported in the Medicines Company media release.